Oncological complications of human immunodeficiency virus disease and hematologic consequences of their treatment

Clinical Infectious Diseases

Volumn 29, Issue 1, 1999, Pages 35-43

  Mitsuyasu, Ronald ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GROWTH FACTOR;

ANUS TUMOR; CANCER; CONFERENCE PAPER; CYTOPENIA; EPSTEIN BARR VIRUS; HEMATOLOGIC DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 0032794579     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520177     Document Type: Conference Paper

References (77)

1. 1. Palella FJ Jr, Delaney KM, Moorman C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. 2. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
3. 3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
4. 4. Chaisson RE, Moore RD. Prevention of opportunistic infections in the era of improved antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16(suppl 1):S14-22.
5. 5. Centers for Disease Control and Prevention. Update: trends in AIDS incidence - United States, 1996. JAMA 1997;278:1485-6.
6. 6. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
7. 7. Lee FC, Cooper JS, Mitsuyasu RT. AIDS-related malignancies. In: Cancer management: a multidisciplinary approach. 2nd ed. Huntington, NY: PRR, 1998:537-63.
8. 8. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335:123-8.
9. 9. Serraino D, Franceschi S, Tirelli U, Monfardini S. The epidemiology of acquired immunodeficiency syndrome and associated tumours in Europe. Ann Oncol 1992;3:595-603.
10. 10. Elford J, McDonald A, Kaldor J, National HIV Surveillance Committee. Kaposi's sarcoma as a sexually transmissible infection: an analysis of Australian AIDS surveillance data. AIDS 1993;7:1667-71.
11. 11. Cesarman E, Knowles DM. Kaposi's sarcoma - associated herpesvirus: a lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Semin Diagn Pathol 1997;14:54-66.
12. 12. Nasti G, Vaccher E, Errante D, Tirelli U. Malignant tumors and AIDS. Biomed Pharmacother 1997;51:243-51.
13. 13. Ambroziak JA, Blackbourn DJ, Herndier BG, et al. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 1995;268:582-3.
14. 14. Heredia A, Vallejo A, Hewlett IK, et al. Detection of herpesvirus type 8 (HHV-8) sequences in patients with Kaposi's sarcoma in Spain [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:310-1.
15. 15. Cesarman E, Nador RG, Bai F, et al. Kaposi's sarcoma associated herpesvirus contains G protein - coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J Virol 1996;70:8218-23.
16. 16. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998;338:948-54.
17. 17. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995;346:799-802.
18. 18. Moore PS, Kingsley LA, Holmberg SD, et al. Kaposi's sarcoma associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 1996;10:175-80.
19. 19. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma associated herpesvirus (HIIV8). Proc Natl Acad Sci USA 1996;93:14862-7.
20. 20. Sung JCY, Louie SG, Park SY. Kaposi's sarcoma: advances in tumor biology and pharmacotherapy. Pharmacotherapy 1997;17:670-83.
21. 21. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989;7:1201-7.
22. 22. Krown SE, Tosta MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the ACTG staging classification. J Clin Oncol 1997;15:3085-92.
23. 23. Lee FC, Mitsuyasu RT. Chemotherapy of AIDS-related Kaposi's sarcoma. Hematol Oncol Clin North Am 1996;10:1051-68.
24. 24. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996;14:2353-64.
25. 25. Northfelt DW, Dezube B, Thomas JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997;15:653-9.
26. 26. Goebel FD, Goldstein D, Goos M, et al. Efficacy and safely of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br J Cancer 1996;73:989-94.
27. 27. Coté TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer 1997;73:645-50.
28. 28. Straus DJ. HIV-associated lymphomas. Curr Opin Oncol 1997;9:450-4.
29. 29. Straus DJ. Human immunodeficiency virus-associated lymphomas. Med Clin North Am 1997;81:495-510.
30. 30. Karcher DS, Alkan S. Human herpesvirus-8-associated body cavity based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm. Hum Pathol 1997;28:801-8.
31. 31. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997;336:1641-8.
32. 32. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989;261:719-24.
33. 33. Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991;68:2466-72.
34. 34. Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991;9:929-40.
35. 35. Walsh C, Wernz JC, Levine A, et al. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 1993;6:265-71.
36. 36. Cingolani A, DeLuca A, Larocca LM, et al. Minimally invasive diagnosis of AIDS-related primary central nervous system lymphoma. J Natl Cancer Inst 1998;90:364-9.
37. 37. Corn BW, Donahue BR, Rosenstock JG, et al. Palliation of AIDS-related primary lymphoma of the brain: observations from a multi-institutional database. Int J Radiat Oncol Biol Phys 1997;38:601-5.
38. 38. O'Brien PC, Roos DE, Liew KH, et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Med J Aust 1996;165:424-7.
39. 39. Wright TC Jr, Sun XW. Anogenital papillomavirus infection and neoplasia in immunodeficient women. Obstet Gynecol Clin North Am 1996;23:861-93.
40. 40. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1993;41:1.
41. 41. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC Jr. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.
42. 42. Maiman M, Fruchter RG, Clark M, Arrastia CD, Matthews R, Gates EJ. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997;89:76-80.
43. 43. Maiman M, Fruchter RG, Serur E, et al. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 1993;82:170-4.
44. 44. Boccalon M, Tirelli U, Sopracordevole F, Vaccher E. Intra-epithelial and invasive cervical neoplasia during HIV infection. Eur J Cancer 1996;32A:2212-7.
45. 45. Palefsky JM, Holly EA. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4:415-28.
46. 46. Vermund SH, Kelley KF, Klein RS, et al. High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 1991;165:392-400.
47. 47. Johnson JC, Burnett AF, Willet GD, Young MA, Doniger J. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet Gynecol 1992;79:321-7.
48. 48. Palefsky JM, Barrasso R. HPV infection and disease in men. Obstet Gynecol Clin North Am 1996;23:895-916.
49. 49. Palefsky J. Human papillomavirus infection among HIV-infected individuals: implications for development of malignant tumors. Hematol Oncol Clin North Am 1991;5:357-70.
50. 50. Mitsuyasu RT. Hematologic complications of HIV infection. In: Dolin R, Masur H, Saag M, eds. AIDS therapy. Philadelphia: Churchill Livingstone, 1999:666-79.
51. 51. Aboulafia DM. Use of hematopoietic hormones for bone marrow defects in AIDS. Oncology 1997;11:1827-44.
52. 52. Harris CE, Biggs JC, Concannon AJ, Dodds AJ. Peripheral blood and bone marrow findings in patients with acquired immune deficiency syndrome. Pathology 1990;22:206-11.
53. 53. Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:175-80.
54. 54. Fauci AS, Lane HC. Human immunodeficiency virus (HIV) disease: AIDS and related disorders. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:1566-618.
55. 55. Hambleton J. Hematologic complications of HIV infection. Oncology 1996;10:671-80.
56. 56. Calenda V, Chermann JC. The effects of HIV on hematopoiesis. Eur J Haematol 1992;48:181-6.
57. 57. Mitsuyasu RT. Hematopoietic growth factors in the treatment of patients with HIV infection. Biotherapy 1990;2:173-81.
58. 58. Glaspy JA, Chap L. The clinical application of recombinant erythropoietin in the HIV-infected patient. Hematol Oncol Clin North Am 1994;8:945-59.
59. 59. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;332:1488-93.
60. 60. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immune deficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993;33:111-8.
61. 61. Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996;36:860-5.
62. 62. Henry DH, Beall GN, Benson CA. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med 1992;117:739-48.
63. 63. Miles SA. The use of hematopoietic growth factors in HIV infection and AIDS-related malignancies. Cancer Invest 1991;9:229-38.
64. 64. Murphy PM, Lane C, Fauci AS, Gallin JL Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis 1988;158:627-30.
65. 65. Valone FH, Payan DG, Abrams DI, Goetzl EF. Defective polymorphonu-clear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome. J Infect Dis 1984;150:267-71.
66. 66. Pitrak DL, Bak PM, DeMarais P, et al. Depressed neutrophil superoxide production in human immunodeficiency virus infection. J Infect Dis 1993;167:1406-10.
67. 67. Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis 1988;158:1268-76.
68. 68. Shaunak S, Bartlett JA. Zidovudine-induced neutropenia: are we too cautious? Lancet 1989;2:91-2.
69. 69. Moore RD, Keruly JC, Chaisson RE. Neutropenia and bacterial infection in acquired immunodeficiency syndrome. Arch Intern Med 1995;155:1965-70.
70. 70. Jacobson MA, Liu RC, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med 1997;157:1825-31.
71. 71. Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 1998;12:65-74.
72. 72. Garavelli PI, Berti P. Efficacy of recombinant granulocyte colony-stimulating factor in the long-term treatment of AIDS-related neutropenia. AIDS 1993;7:589-600.
73. 73. Kimura S, Matsuda J, Ikematsu S, et al. Efficacy of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with AIDS. AIDS 1990;4:1251-5.
74. 74. Keiser P, Rademacher S, Smith JW, Skiest D, Vadde V. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 1998;104:48-55.
75. 75. Krown SE, Paredes J, Bundow D, Polsky B, Gold JWM, Flomenberg N. Interferon-α, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS clinical trials group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 1992;10:1344-51.
76. 76. Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991;68:2466-72.
77. 77. Koyanagi Y, O'Brien WA, Zhao JQ, et al. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988;241:1673-5.